News Moberg Pharma AB

Equities

Delayed Nasdaq Stockholm Other stock markets 08:21:09 2024-05-07 am EDT			5-day change	1st Jan Change
37.28 ^SEK	-4.21%		+9.20%	+145.26%

Apr. 23	Moberg Pharma AB Announces Launch Update for Mob-015	CI
Apr. 08	Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	CI

Moberg Pharma's interim report January - March 2024	02:01am	AQ
National approval for MOB-015 in all 13 countries	May. 06	AQ
Moberg Pharma : Launch update for MOB-015	Apr. 23	PU
Moberg Pharma : Launch update for MOB-015	Apr. 23	PU
Moberg Pharma AB Announces Launch Update for Mob-015	Apr. 23	CI
Notice of Annual General Meeting in Moberg Pharma AB (publ)	Apr. 12	AQ
Moberg Pharma Annual report for 2023	Apr. 12	AQ
Moberg Pharma : Corporate Governance Report 2023	Apr. 12	PU
Moberg Pharma : Application submitted to include an additional terbinafine supplier	Apr. 08	PU
Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	Apr. 08	CI
Certain Ordinary Shares of Moberg Pharma AB are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
The Nomination Committee's proposal to the Annual General Meeting 2024	Feb. 19	AQ
Moberg Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13	CI
Moberg Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication	Feb. 07	AQ
Moberg Pharma's Interim report January - September 2023	Nov. 07	AQ
Moberg Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Moberg Pharma strengthens the organization	Nov. 07	AQ
Moberg Pharma Announces Leadership Changes	Nov. 07	CI
Moberg Pharma's Nomination Committee appointed	23-10-17	AQ

No results for this search